GLP-1 Therapy: Cardiometabolic Benefit With Nutritional Vigilance

Clinical Mastery · Visual teaching summary · October 3, 2026

Andrew Bland, MD, FACP, FAAP

Visual summary

Different agents and populations have different outcome evidence. Confirm the actual paper before quoting a kidney endpoint or applying one study to every class member.

Track health and function alongside weight. See the diagram description and full text below.
· Download full-size illustration (PNG) · Download Markdown · Read text version ·

Illustration updated October 18, 2026. Educational schematic. Imaging and microscopy panels are illustrations, not patient studies. Full teaching text and sources follow.

Diagram description

Track health and function alongside weight. GLP-1 therapy — Cardiometabolic indication and eligibility; Appetite and intake — Assess nausea, hydration and nutrition; Muscle and function — Protect adequate food intake and activity; Meaningful response — Weight, glucose, kidney context and daily ability. Weight loss alone is not a complete measure of benefit or tolerance. The infographic uses anatomical illustrations and integrated labels; the complete teaching text and evidence are below.

Text version

Multiple pathways

GLP-1 receptor agonists affect glucose regulation, appetite, weight, and cardiometabolic risk. Kidney effects must be interpreted within the specific trial and clinical population.

Define the treatment goal

Consider glycemic control, obesity-related burden, cardiovascular risk, and CKD alongside patient priorities and tolerability.

Recognize intolerance that changes treatment

Persistent vomiting, reduced intake, orthostasis, or falling urine output should prompt assessment for dehydration and medication-related AKI. Review diuretics and other interacting illness risks. Monitor weight alongside muscle strength and food intake so loss of lean tissue is not counted as an uncomplicated success.

Follow beyond body weight

Monitor hydration, kidney function when clinically indicated, nutritional intake, strength, and functional capacity. Weight loss is not always equivalent to improved health.

Coordinate care

Dietary support, activity suited to the patient, and medication review can help preserve function during treatment. Acute illness and procedures may require specific advice.

Apply the actual kidney-outcome evidence

FLOW tested semaglutide in people with type 2 diabetes and CKD. Do not generalize its kidney outcome automatically to every GLP-1 agent, people without diabetes, or dialysis. Select treatment for the person’s indication and assess gastrointestinal tolerance, hypoglycemia risk with co-therapy, and nutrition.

Continue learning